Neurocrine Biosciences Inc. (NYSE: NBIX) announced Monday its phase II drug candidate to treat endometriosis achieved main and secondary goals. Endometriosis is diagnosed in women mostly between the ages of 25 and 35 who experience varying levels of pelvic pain associated with the uterine lining growing outside the womb, a condition with no cure and [...]